GUILLERMO LÓPEZ VIVANCO-rekin lankidetzan egindako argitalpenak (111)

2023

  1. Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer (Scientific Reports, (2015), 5, 1, (17499), 10.1038/srep17499)

    Scientific Reports

  2. Differences in Quality of Life and Emotional Well-being in Breast, Colon, and Lung Cancer Patients During Outpatient Adjuvant Chemotherapy: A Longitudinal Study

    Cancer Nursing, Vol. 46, Núm. 2, pp. E99-E109

  3. Immunogenicity of COVID-19 vaccines in lung cancer patients

    Lung Cancer, Vol. 184

  4. Nurse-Supervised Exercise for People with Stage IV Cancer: The EFICANCER Randomized Clinical Trial

    Seminars in Oncology Nursing, Vol. 39, Núm. 4

  5. Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer

    New England Journal of Medicine, Vol. 389, Núm. 6, pp. 504-513

2022

  1. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

    Annals of Oncology, Vol. 33, Núm. 1, pp. 67-79

  2. Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)

    Lung Cancer, Vol. 173, pp. 83-93

  3. Just an Acute Pulmonary Edema? Paraneoplastic Thyroid Storm Due to Invasive Mole

    Case Reports in Oncology, Vol. 15, Núm. 2, pp. 566-572

  4. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

    Journal of Clinical Oncology, Vol. 71

  5. Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study

    Translational Lung Cancer Research, Vol. 11, Núm. 1, pp. 53-63

  6. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

    Journal for immunotherapy of cancer, Vol. 10, Núm. 9

2021

  1. Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 8

  2. First-line osimertinib in patients with epidermal growth factor receptor–mutant non–small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met

    European Journal of Cancer, Vol. 159, pp. 174-181

  3. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study

    Cancer Chemotherapy and Pharmacology, Vol. 87, Núm. 4, pp. 543-553

  4. Pretreatment tissue TCR repertoire evenness is associated with complete pathologic response in patients with NSCLC receiving neoadjuvant chemoimmunotherapy

    Clinical Cancer Research, Vol. 27, Núm. 21, pp. 5878-5890

2020

  1. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

    The Lancet Oncology, Vol. 21, Núm. 11, pp. 1413-1422

2019

  1. Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer

    Journal of Thoracic Oncology, Vol. 14, Núm. 2, pp. 304-310

  2. Germline c.1A>C heterozygous pathogenic variant in SDHA reported for the first time in a young adult with a gastric gastrointestinal stromal tumour (GIST): A case report

    Hereditary Cancer in Clinical Practice, Vol. 17, Núm. 1

2018

  1. Aportación del uso medicinal de los derivados del cannabis: una revisión de su potencial eficacia clínica y riesgos

    Gaceta médica de Bilbao: Revista oficial de la Academia de Ciencias Médicas de Bilbao. Información para profesionales sanitarios, Vol. 115, Núm. 2, pp. 83-95

  2. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS

    Clinical and Translational Oncology, Vol. 20, Núm. 10, pp. 1261-1267